Skip to content
2000
Volume 12, Issue 2
  • ISSN: 1871-5281
  • E-ISSN: 2212-4055

Abstract

Inhaled therapeutics are used routinely to treat a variety of pulmonary diseases including asthma, COPD and cystic fibrosis. In addition, biological therapies represent the fastest growing segment of approved pharmaceuticals. However, despite the increased availability of biological therapies, nearly all inhaled therapeutics are small molecule drugs with only a single inhaled protein therapeutic approved. There remains a significant unmet need for therapeutics in pulmonary diseases, and biological therapies with potential to alter disease progression represent a significant opportunity to treat these challenging diseases. This review provides a background into efforts to develop inhaled biological therapies and highlights some of the associated challenges. In addition, we speculate on the ideal properties of a biologic therapy for inhaled delivery.

Loading

Article metrics loading...

/content/journals/iadt/10.2174/1871528111312020002
2013-04-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/iadt/10.2174/1871528111312020002
Loading

  • Article Type:
    Research Article
Keyword(s): Alternative scaffolds; inhalation; protein therapeutics; pulmonary delivery
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test